Low BRMS1 expression promotes nasopharyngeal carcinoma metastasis in vitro and in vivo and is associated with poor patient survival

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Cui, Rui Xue ^a   Liu, Na ^a   He, Qing Mei ^a   Li, Wen Fei ^a   Huang, Bi Jun ^a   Sun, Ying ^a   Tang, Ling Long ^a   Chen, Mo ^a   Jiang, Ning ^a   Chen, Lei ^a   Yun, Jing Ping ^a   Zeng, Jing ^a   Guo, Ying ^a   Wang, Hui Yun ^a   Ma, Jun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

BRMS1; Metastasis; Nasopharyngeal carcinoma; Prognosis

Indexed keywords

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER METASTASIS SUPPRESSOR 1 GENE; CANCER CELL; CANCER PROGNOSIS; CELL INVASION; CONTROLLED STUDY; DISTANT METASTASIS; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS FREE SURVIVAL; MIGRATION INHIBITION; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; OVERALL SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865442100     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-376     Document Type: Article

References (32)

1. Aea J. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002, 12(6):421-429. 10.1016/S1044579X02000858, 12450728.
3. Kwong DL, Sham JS, Au GK, Chua DT, Kwong PW, Cheng AC, Wu PM, Law MW, Kwok CC, Yau CC, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 2004, 22(13):2643-2653. 10.1200/JCO.2004.05.173, 15226332.
4. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, Chua ET, Yang E, Lee KM, Fong KW, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005, 23(27):6730-6738. 10.1200/JCO.2005.16.790, 16170180.
5. Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P, Weinberg V, Fu KK. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002, 53(1):12-22. 10.1016/S0360-3016(02)02724-4, 12007936.
6. Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, Sun Y, Lin AH, Liu MZ, Ma J. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?. Int J Radiat Oncol Biol Phys 2011, 80(3):661-668. 10.1016/j.ijrobp.2010.03.024, 20643517.
7. Germanov E, Berman JN, Guernsey DL. Current and future approaches for the therapeutic targeting of metastasis (review). Int J Mol Med 2006, 18(6):1025-1036.
8. Seraj MJ, Samant RS, Verderame MF, Welch DR. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res 2000, 60(11):2764-2769.
9. Shevde LA, Samant RS, Goldberg SF, Sikaneta T, Alessandrini A, Donahue HJ, Mauger DT, Welch DR. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res 2002, 273(2):229-239. 10.1006/excr.2001.5452, 11822878.
10. Li J, Cheng Y, Tai D, Martinka M, Welch DR, Li G. Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis. Oncogene 2011, 30(8):896-906. 10.1038/onc.2010.470, 3235331, 20935672.
11. Zhang S, Lin QD, Di W. Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1. Int J Gynecol Cancer 2006, 16(2):522-531. 10.1111/j.1525-1438.2006.00547.x, 16681721.
12. Seraj MJ, Harding MA, Gildea JJ, Welch DR, Theodorescu D. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metastasis 2000, 18(6):519-525. 10.1023/A:1011819621859, 11592309.
13. Smith PW, Liu Y, Siefert SA, Moskaluk CA, Petroni GR, Jones DR. Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer. Cancer Lett 2009, 276(2):196-203. 10.1016/j.canlet.2008.11.024, 19111386.
14. Liao WT, Song LB, Zhang HZ, Zhang X, Zhang L, Liu WL, Feng Y, Guo BH, Mai HQ, Cao SM, et al. Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Clin Cancer Res 2007, 13(2 Pt 1):508-514.
15. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17(6):1471-1474. 10.1245/s10434-010-0985-4, 20180029.
16. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004, 10(24):8465-8471. 10.1158/1078-0432.CCR-04-0653, 15623626.
17. Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007, 60(10):1112-1116. 10.1136/jcp.2006.044537, 2014838, 17182662.
18. Stark AM, Tongers K, Maass N, Mehdorn HM, Held-Feindt J. Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases. J Cancer Res Clin Oncol 2005, 131(3):191-198. 10.1007/s00432-004-0629-9, 15592684.
19. Hicks DG, Yoder BJ, Short S, Tarr S, Prescott N, Crowe JP, Dawson AE, Budd GT, Sizemore S, Cicek M, et al. Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. Clin Cancer Res 2006, 12(22):6702-6708. 10.1158/1078-0432.CCR-06-0635, 1661839, 17121889.
20. Metge BJ, Liu S, Riker AI, Fodstad O, Samant RS, Shevde LA. Elevated osteopontin levels in metastatic melanoma correlate with epigenetic silencing of breast cancer metastasis suppressor 1. Oncology 2010, 78(1):75-86. 10.1159/000292363, 20215788.
21. Nagji AS, Liu Y, Stelow EB, Stukenborg GJ, Jones DR. BRMS1 transcriptional repression correlates with CpG island methylation and advanced pathological stage in non-small cell lung cancer. J Pathol 2010, 221(2):229-237. 10.1002/path.2707, 2933360, 20455258.
22. Liu Y, Mayo MW, Nagji AS, Smith PW, Ramsey CS, Li D, Jones DR. Phosphorylation of RelA/p65 promotes DNMT-1 recruitment to chromatin and represses transcription of the tumor metastasis suppressor gene BRMS1. Oncogene 2012, 31(9):1145-1154.
23. Kelly LM, Buggy Y, Hill A, O'Donovan N, Duggan C, McDermott EW, O'Higgins NJ, Young L, Duffy MJ. Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes. Tumour Biol 2005, 26(4):213-216. 10.1159/000086955, 16006775.
24. Li J, Li G. Cell cycle regulator ING4 is a suppressor of melanoma angiogenesis that is regulated by the metastasis suppressor BRMS1. Cancer Res 2010, 70(24):10445-10453. 10.1158/0008-5472.CAN-10-3040, 21056991.
25. Zhang Z, Yamashita H, Toyama T, Yamamoto Y, Kawasoe T, Iwase H. Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer. Clin Cancer Res 2006, 12(21):6410-6414. 10.1158/1078-0432.CCR-06-1347, 17085653.
26. Lombardi G, Di Cristofano C, Capodanno A, Iorio MC, Aretini P, Isola P, Tancredi M, Collecchi P, Naccarato AG, Porta RP, et al. High level of messenger RNA for BRMS1 in primary breast carcinomas is associated with poor prognosis. Int J Cancer 2007, 120(6):1169-1178. 10.1002/ijc.22379, 17163420.
27. Metge BJ, Frost AR, King JA, Dyess DL, Welch DR, Samant RS, Shevde LA. Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer. Clin Exp Metastasis 2008, 25(7):753-763. 10.1007/s10585-008-9187-x, 2763604, 18566899.
28. Meehan WJ, Samant RS, Hopper JE, Carrozza MJ, Shevde LA, Workman JL, Eckert KA, Verderame MF, Welch DR. Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J Biol Chem 2004, 279(2):1562-1569.
29. Cicek M, Fukuyama R, Welch DR, Sizemore N, Casey G. Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity. Cancer Res 2005, 65(9):3586-3595. 10.1158/0008-5472.CAN-04-3139, 15867352.
30. Cicek M, Fukuyama R, Cicek MS, Sizemore S, Welch DR, Sizemore N, Casey G. BRMS1 contributes to the negative regulation of uPA gene expression through recruitment of HDAC1 to the NF-kappaB binding site of the uPA promoter. Clin Exp Metastasis 2009, 26(3):229-237. 10.1007/s10585-009-9235-1, 2756239, 19165610.
31. Vaidya KS, Harihar S, Phadke PA, Stafford LJ, Hurst DR, Hicks DG, Casey G, DeWald DB, Welch DR. Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling. J Biol Chem 2008, 283(42):28354-28360. 10.1074/jbc.M710068200, 2661398, 18664570.
32. Samant RS, Clark DW, Fillmore RA, Cicek M, Metge BJ, Chandramouli KH, Chambers AF, Casey G, Welch DR, Shevde LA. Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol Cancer 2007, 6:6. 10.1186/1476-4598-6-6, 1796551, 17227585.